Renal and GU cancers and prostate cancers Flashcards
What is the most common renal cancer?
Renal cell carcinoma
What is Transitional Cell Carcinoma
From urothelium – transitional epithelium
Rare occurrence in renal pelvis or ureter, common in bladder
What is the commonest abdominal tumour of childhood?
Wilm’s Tumour – nephroblastoma
What is Angiomyolipoma?
Benign renal tumour
Mesenchymal tumour full of blood vessels, smooth muscle & fat
What is oncocytoma?
Benign renal mass (BRM)
Thought to arise from intercalated cells of collecting duct
Simultaneous with RCC in 7-32%
Surveillance if biopsy proven, partial nephrectomy if in doubt
What is renal cell carcinoma?
Adenocarcinoma
Histological subtypes of renal cell carcinoma
Clear cell, papillary, chromophobe, collecting duct
Metastasis of RCC
Local invasion
Invasion of renal vein (tumour thrombus as far as right atrium!)
Lung (cannonball), brain or bone mets
Which gender more likely to have renal cell carcinoma
Females more than males
Risk factors for RCC?
- smoking
- obesity
- renal failure
- HTN
- social deprivation
Genetic causes of RCC
VHL syndrome – autosomal dominant
Paraneoplastic syndromes for RCC
Anaemia/polycythaemia 30%/5%
Hypertension 25%,
hypercalcaemia 20%,
Hypoglycaemia
Stauffer’s syndrome: hepatic dyfunction + fever + anorexia
Investigations for RCC
CT is gold standard imaging
FBC (polycythaemia/anaemia) U&E, LFT, Coag etc
Needle biopsy if diagnosis in doubt
classic triad of symptoms for renal cell carcinoma
flank pain
haematuria
abdo mass
Management of RCC?
Partial nephrectomy - Gold standard for small tumours confined to kidney
Radical nephrectomy
Palliative options
Adjuvant treatments
Presentation of Upper Tract Transitional Cell Carcinoma
Haematuria 80%, Loin pain 30% often “clot colic”
Management of Upper Tract Transitional Cell Carcinoma
Nephroureterectomy is gold standard curative treatment
Local treatment with ureteroscopy and laser of small lesions
General symptoms of kidney cancer
- haematuria
- loin pain
- mass
Treatment for renal cancers such as RCC
Surgical
Does not respond to radiotherapy
Upper tract / kidney TCC has the same pathology as what?
Bladder cancer
Bladder cancer pathologies
Transitional Cell Carcinoma (90%): from transitional epithelium - the “urothelium”
Squamous Cell Carcinoma (5% in UK, 75% in Egypt): metaplasia - dysplasia process from irritation eg stones, schistosomiasis
Adenocarcinoma (2%): quite rare
Rarities: Spindle cell carcinoma, melanoma, lymphoma, sarcoma
TCC risk factors
Men 2.5x > Women
Age: >50
Carcinogens: tobacco smoke, rubber, diesel exhaust
Industrial exposure: hairdressers, chemical workers
Drugs eg Phenacetin, Cyclophosphamide, Pioglitazone
TCC grading and staging
Stage:
- Tis carcinoma in situ: superficial but very dangerous
- Ta / T1 papillary non invasive / sub epithelial only: low risk
- T2 muscle invasive
- T3a/b through the muscle / invading perivesical fat
- T4a/b invading prostate / pelvic side wall
Implantation: TCC can spread along incisions/tracts eg SPC tract
Lymph nodes: iliac or para-aortic nodes
Distant Mets: to liver / lung / bone / adrenal
What is Transurethral Resection of Bladder Tumour
Complete resection is adequate for 70% of superficial low risk disease
Controls haematuria in advanced disease
rf for bladder cancer
- occupational exposure to dyes
hairdresser, painter, nail artist
-smoking - chemo and radiotherapy
-male
presentation of bladder cancer
Painless haematuria
gold standard diagnostic test for bladder cancer
flexible cytoscopy
treatment for bladder cancer
conservative= support
medical= chemo or radiotherapy
surgery= TURBT
T1= transurethral resection or local diathermy
T2-3 = Radical cystectomy
T4 = palliative chemo and radiotherapy
What are the risk of Transurethral Resection of Bladder Tumour?
Pain, infection, bladder perforation
Need for 3 way catheter & irrigation for a day or so after big resection
IF a patient has schistosmiasis what would this indicate
more likely to have squamous cell carcinoma than transitional
Differential diagnosis for bladder cancer:
Infection: UTI, pyelonephritis, TB
Malignancy: anywhere in tract
Stones: bladder, kidney, ureteric
Trauma: penetrating Vs Blunt
Nephrological: diabetes, nephropathy (proteinuria)
When do you do a re-resection of of bladder tumour
If incomplete, high grade seemingly non invasive, or no muscle in sample
To be done within 6 weeks
What is mitomicin C
Chemotherapy
Reduces disease recurrence
Minimal side effects
What is BCG? - Vaccination
Reduces disease progression and recurrence
Significant side effects, risk of systemic BCGosis
What surgeries do we use for Muscle invasive bladder cancer?
Radical cystoprostatectomy / cystourethrectomy & lymphadenectomy
This is major surgery, 1% mortality, 33% morbidity
What is TCC commonly caused by?
Smoking and chemical exposure
How is haematuria investigated
flexi cystoscopy and upper tract imaging
Mitomicin C or BCG can be used as what?
as instillations for bladder cancer
What is muscle invasive disease treated by
Cystectomy - major surgery
What is the most common urinary diversion?
Ileal conduit
Mortality of testicular cancer
It is the most curable cancer, extremely sensitive to chemotherapy
Epidemiology of testicular cancer
White caucasians have highest risk
Previous ca testis: 12x increased risk (bilateral in 1-2%)
Cryptorchidism: 6x increased risk
HIV: 33% increased risk of seminoma
Familial increased risk 4 - 8 fold
Pathology of testicular cancer
90% are Germ Cell Tumours:
Seminoma (48%): spermatocytic, classical & anapaestic
Non seminoma (42%): teratoma, yolk sac tumour, choriocarcinoma, mixed
Mixed seminoma and non seminoma (10%): Leydig cell / Sertoli cell
Symptoms of testicular cancer
painless lump in testicle which does not transilluminate
OE for testicular cancer
hard mass arising from testis
Check lymph nodes, abdomen and lungs
rf for testicular cancer
cryptorchidism , infertility, family history
Investigations for testicular cancer
Scrotal USS to be done that day
Tumour markers: AFP, Beta-hCG, LDH
CXR & CTAP or CTCAP staging
Definitive diagnosis and primary treatment of testicular cancer
Radical Inguinal Orchidectomy
When do we Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks)?
Aged 45 and over and have:
Unexplained visible haematuria without urinary tract infection or
Visible haematuria that persists or recurs after successful treatment of urinary tract infection, or
Aged 60 and over and have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test (new NICE recommendation for 2015).
What is more likely non muscle invasive bladder cancer (NMIBC) Invasive MIBC
NMIBC
MI requires what type of treatment if suitable
Cystectomy
Radiotherapy
+/- chemotherapy
NMIBC
70% will recur
15% will progress to MI
So grade:
G1 – well differentiated
G2 - moderate
G3 – poorly differentiated
CIS – carcinoma in situ
RF for NMIBC
Paraplegia
Smoking
Ocuupational
Drugs - phenacetin, aspirin
Bladder stones (Schistosomiasis)
Prognosis of NMIBC
10yr survival 50%
Follow up depends on grade/
Stage.
Based mainly on cystoscopy
Stage 1 renal cancer
Tumour <7cm in largest dimension
Limited to kidney
Management
Partual nephrectomy
Radical nephrectomy
Stage 2 renal cancer
Tumour >7cm in largest dimension
Limited to kidney
Management options
Radical nephrectomy
Partial nephrectomyh
Stage 3 renal cancer
Tumour in major veins or adrenal gland with inttact Gerota’s fascia
Regional lymph nodes involved
Management options
Radical nephrectomy plus adrenalectomy, tumour thrombus excision
Systemic treatment
Stage 4 renal cancer
Tumour beyond Gerota’s fascia
Distant metastases
Management options
Systemic treatment
Elective cytoreductive nephrectomy
Non specific constitutional symptoms
Weight Loss
Anorexia
Fever
Anaemia (normocytic)
Prostate cancer epidemiology
Most commonly diagnosed cancer in men
A disease of the industrialised West.
Mean age at diagnosis 72
Family history in 5 – 10%
12- 16 % lifetime risk of diagnosis
67% of men in their 80s have prostate cancer on routine post mortem examination
3% of men die of prostate cancer
Prostate cancer basics
Adenocarcinoma
Occurs in peripheral zone of prostate
85% of tumours are multifocal
Spreads locally through prostate capsule
Metastasises to lymph nodes and bone (sclerotic) and occasionally to lung, liver and brain
What are the 3 zones of the prostate?
Peripheral
Central
Transitional
What are the biomarkers for prostate cancer?
Tissue
Serum:
Prostate-specific Antigen (PSA)
Prostate-specific membrane antigen (PSMA)
Urine:
PCA3
Gene fusion products (TMPRSS2-ERG)
What is PSA?
Prostate-specific antigen
Small amount of retrograde leakage
Detected in small quantities in the blood
Not cancer specific (prostate specific)
Elevated in benign prostate enlargement, urinary tract infection, prostatitis
PSA stats
70% of men with an elevated PSA will not have prostate cancer
6% of men with prostate cancer will have a ‘normal’ PSA
PSA levels
PSA 8.0 - 9.99 ng/Ml then you have 50% chance of prostate cancer - rises after this level
What do we use to diagnose prostate cancer?
Lower urinary tract symptoms (LUTS)
Prostate specific antigen (PSA)
Transrectal ultrasound scan (TRUSS)
Prostate biopsy
Prostate cancer grading (Gleason grading)
Grading of prostate cancer (Histological)
Gleason grading
Add the 2 most common types of cells in prostate together that you find histologically
Score e.g. 3+4
Higher score more aggressive
What are the stages of prostate cancer diagnosis?
T stage
N stage
M satge
What happens in T stage of prostate cancer staging
Tx - unable to assess size
T1 -no palpable tumour on DRE
T2 -palpable tumour, confined to prostate
T3 -palpable tumour extending beyond prostate
T4 - spread to nearby organs
N stage for prostate cancer staging
NX – unable to assess nodes
N0 – no nodal spread
N1 – spread to lymph nodes
MRI scan, CT scan, (laparoscopy)
M stage for prostate cancer staging
M0 – no metastasis
M1 – metastasis
Bone scan
Prostatate cancer timeline
Presentation (symptoms/PSA) > Diagnosing (Biopsy) > Staging (DRE, MRI/CT & Bone scan) >
1. Localised
2. Locally advanced
3. Metastastic
Localised prostate cancer
PSA detected disease
Occasionally detected during surgery for benign prostatic obstruction
Transrectal ultrasound and biopsy of prostate gland
No clinical evidence of metastatic disease
What happens in localised prostate cancer
1.Curative >
a.Surgery - radical prostatectomy open, laparoscopic, robotic
b. radiotherapy - external beam, brachytherapy
c. adjuvant hormones
d. focal therapy
2. Observation
What happens in local control of prostate cancer
Surgery
Radiotherapy + neoadjuvant hormone therapy
Metastatic prostate cancer
Palliative > Hormone therapy
Screening for prostate cancer
Before PSA, common presentation with advanced disease (>60%) (T3 or T4)
Commonest site of metastasis – bone (M1)
Currently majority of cases are T1c
Detected on PSA testing
Reasons for screening for prostate cancer
Commonest cancer in men – lifetime risk c. 9%
Responsible for 10,000 deaths per annum in UK.
4th most common cause of cancer death.
3% of men will die of prostate cancer.
Reasons against screening for prostate cancer
Uncertain natural history
Overtreatment
Morbidity of treatment
Benefitst and risk of PSA testing
Benefits:
Early diagnosis of localised disease (cure)
Early treatment of advanced disease (effective palliation)
Risks:
Overdiagnosis of insignificant disease
Harm caused by investigation/ treatment
Advanced disease of prostate cancer
Locally advanced
Radiotherapy
Radical prostatectomy
Metastatic disease
Treatment for metastatic prostate cancer
Surgical castration:
Reduced pain due to bony metastases
Prolonged survival
Median survival 2.5 years
Prognosis of advanced prostate cancer
Median survival 2.5 years but significant number of long-term ‘remission’ on androgen deprivation therapy
FAR BETTER PALLIATION THAN AVAILABLE FOR MOST METASTATIC SOLID TUMOURS
80% androgen-sensitive
Castration leads to remission of advanced disease (apoptosis of cancer cells)
Median response 2 years
Castration-resistant phase
Castration-resistant prostate cancer
2nd line hormone therapy:
Abiraterone
Enzalutamide
Cytotoxic chemotherapy - Docetaxel, Carbazitaxel
Key risk factors of prostate cancer
Increasing age
Family history
Black African or Caribbean origin
Tall stature
Anabolic steroids
Presentation of prostate cancer
May be Asymptomatic
LUTS
Haematuria
Erectile dysfunction
Symptoms of advanced disease or metastasis
What produces PSA
epithelial cells of the prostate
Glycoprotein secreted in semen - small amount in blood
Why is PSA testing unreliable?
high rate of false positives (75%) and false negatives (15%).
First line investigation used for suspected localised prostate cancer?
Multiparametric MRI
Gleason score results
6 is considered low risk
7 is intermediate risk (3 + 4 is lower risk than 4 + 3)
8 or above is deemed to be high risk